Wednesday - December 10, 2025

Category Archives: Science

Follicular Lymphoma Clinical Trial Pipeline Shows Potential with Active Contributions from 45+ Key Companies | DelveInsight

DelveInsight’s, “Follicular Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Thyroid Cancer Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Thyroid Cancer Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 51+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Acute Lymphocytic Leukemia Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Lupus Nephritis Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Lupus Nephritis Pipeline Insight 2025” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Small Lymphocytic Lymphoma Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Epilepsy Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Epilepsy Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline … Continue reading →

Diarrhea Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Diarrhea Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Diarrhea pipeline landscape. It covers the Diarrhea Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diarrhea Pipeline … Continue reading →

Musculoskeletal Pain Treatment Market Size (7MM) is expected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Musculoskeletal Pain Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of musculoskeletal pain epidemiology, market, and clinical development in musculoskeletal pain. In addition to this, the report provides historical and forecasted epidemiology and market … Continue reading →

ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is expanding its radiotherapeutic platform beyond hematologic cancers with ATNM-400, a next-generation candidate designed to deliver targeted radiation against B7-H3, an immune-checkpoint molecule highly expressed across multiple solid tumors. B7-H3 overexpression is linked to … Continue reading →